KOLEK, Vítězslav, Oldřich FISCHER, Ivona GRYGÁRKOVÁ, M. BAŘINOVÁ, Renata CHLOUPKOVÁ, J. KREJČÍ, Michal HRNČIARIK, Miloš PEŠEK, Jaromír ROUBEC, I. JANÍČKOVÁ, Jana SKŘIČKOVÁ, Marcela TOMÍŠKOVÁ, Leona KOUBKOVÁ, Dimka SIXTOVÁ, M. ČERNOVSKÁ, L. HAVEL, M. ZEMANOVÁ, Helena ČOUPKOVÁ, D. DOLEŽAL and T. TŮZOVÁ. Léčba maligního mezoteliomu pleury v České republice (Treatment of malignant pleural mesothelioma in the Czech Republic). Studia pneumologica et phthiseologica. Praha: Trios s.r.o., 2019, vol. 79, No 3, p. 82-87. ISSN 1213-810X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Léčba maligního mezoteliomu pleury v České republice
Name (in English) Treatment of malignant pleural mesothelioma in the Czech Republic
Authors KOLEK, Vítězslav (203 Czech Republic, guarantor), Oldřich FISCHER (203 Czech Republic), Ivona GRYGÁRKOVÁ (203 Czech Republic, belonging to the institution), M. BAŘINOVÁ (203 Czech Republic), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), J. KREJČÍ (203 Czech Republic), Michal HRNČIARIK (203 Czech Republic), Miloš PEŠEK (203 Czech Republic), Jaromír ROUBEC (203 Czech Republic), I. JANÍČKOVÁ (203 Czech Republic), Jana SKŘIČKOVÁ (203 Czech Republic, belonging to the institution), Marcela TOMÍŠKOVÁ (203 Czech Republic), Leona KOUBKOVÁ (203 Czech Republic), Dimka SIXTOVÁ (203 Czech Republic), M. ČERNOVSKÁ (203 Czech Republic), L. HAVEL (203 Czech Republic), M. ZEMANOVÁ (203 Czech Republic), Helena ČOUPKOVÁ (203 Czech Republic), D. DOLEŽAL (203 Czech Republic) and T. TŮZOVÁ (203 Czech Republic).
Edition Studia pneumologica et phthiseologica, Praha, Trios s.r.o. 2019, 1213-810X.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30203 Respiratory systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/19:00110659
Organization unit Faculty of Medicine
Keywords (in Czech) maligní mezotemiom pleury; chemoterapie; přežití; prognostické faktory
Keywords in English Chemotherapy; Malignant pleural mesothelioma; Survival prognostic factors
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/4/2020 07:06.
Abstract
Malignant pleural mesothelioma (MPM) is the most frequent primary tumor of this anatomical structure. It is usually caused by exposure to asbestos and the incidence continues to rise despite the fact that work with asbestos is banned in European countries. Presented is a set of data on consecutive patients treated with standard first-line cisplatin/pemetrexed chemotherapy in Czech centers. Another sample comprised patients receiving second-line pemetrexed therapy. Data from 2008-2018 were analyzed at the Institute of Biostatistics and Analyses in Brno. The study included 249 and 35 patients receiving first- A nd second-line therapy, respectively. There were 66 females and 183 males with a mean age of 64 years. Occupational and non-occupational exposure to asbestos was confirmed in 58 and 23 cases, respectively; no exposure was found in 168 patients. The most common histological types were epithelioid MPM in 167 patients, mixed in 26 and sarcomatoid in 16 patients; no histological type was determined in 40 subjects. There were 23 patients with TNM stage I, 41 with stage II, 64 with stage III and 115 with stage IV. For the entire sample, the median progression-free survival was 9.6 months and median overall survival (OS) was 20.1 months. Patient survival was affected by the TNM stage and histological type of the tumor. For the second-line therapy, the median OS was 9.9 months. It may be concluded that the prognosis of patients with malignant mesothelioma is still not satisfactory and new treatment options need to be sought. Comments on outcomes of some recent studies are added. © 2019 Trios spol. s.r.o.. All rights reserved.
Abstract (in English)
Malignant pleural mesothelioma (MPM) is the most frequent primary tumor of this anatomical structure. It is usually caused by exposure to asbestos and the incidence continues to rise despite the fact that work with asbestos is banned in European countries. Presented is a set of data on consecutive patients treated with standard first-line cisplatin/pemetrexed chemotherapy in Czech centers. Another sample comprised patients receiving second-line pemetrexed therapy. Data from 2008-2018 were analyzed at the Institute of Biostatistics and Analyses in Brno. The study included 249 and 35 patients receiving first- A nd second-line therapy, respectively. There were 66 females and 183 males with a mean age of 64 years. Occupational and non-occupational exposure to asbestos was confirmed in 58 and 23 cases, respectively; no exposure was found in 168 patients. The most common histological types were epithelioid MPM in 167 patients, mixed in 26 and sarcomatoid in 16 patients; no histological type was determined in 40 subjects. There were 23 patients with TNM stage I, 41 with stage II, 64 with stage III and 115 with stage IV. For the entire sample, the median progression-free survival was 9.6 months and median overall survival (OS) was 20.1 months. Patient survival was affected by the TNM stage and histological type of the tumor. For the second-line therapy, the median OS was 9.9 months. It may be concluded that the prognosis of patients with malignant mesothelioma is still not satisfactory and new treatment options need to be sought. Comments on outcomes of some recent studies are added. © 2019 Trios spol. s.r.o.. All rights reserved.
PrintDisplayed: 16/6/2024 15:34